NICE (UK) recommends upadacitinib as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults
NICE recommendation for upadacitinib as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if: i. tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and iithe company provides upadacitinib according to the commercial arrangement
Usual treatment for active ankylosing spondylitis in adults that is not controlled well enough with conventional therapy, and when TNF-alpha inhibitors are not suitable or do not control the condition well enough, is secukinumab or ixekizumab. Upadacitinib is another treatment that works in a similar way.
Evidence from clinical trials shows that upadacitinib is more effective than placebo. Indirect comparisons of upadacitinib with secukinumab and ixekizumab suggest they have similar clinical effectiveness. A cost comparison suggests upadacitinib has similar costs and overall health benefits as secukinumab and ixekizumab. So upadacitinib is recommended for treating active ankylosing spondylitis in adults if it is used in the same population as secukinumab and ixekizumab.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins